1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,795 | 0,910 | 01.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Arecor Therapeutics raises £5 million through share placement | 1 | Investing.com | ||
| Mi | Arecor Therapeutics nimmt 5 Millionen Pfund über Kapitalerhöhung ein | 1 | Investing.com Deutsch | ||
| ARECOR THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Arecor Therapeutics - Retail Offer to raise up to £130,000 | - | RNS | ||
| Mi | Arecor Therapeutics - Results of Placing | - | RNS | ||
| Mi | Arecor Therapeutics - Close of Accelerated Bookbuild to New Orders | - | RNS | ||
| Mi | EARNINGS: Arecor fundraise as loss widens; Northcoders' B2B progress | 2 | Alliance News | ||
| Mi | Arecor Therapeutics plant Kapitalbeschaffung von bis zu 5,13 Millionen Pfund | 2 | Investing.com Deutsch | ||
| Mi | Arecor Therapeutics plans fundraising of up to £5.13 million | 3 | Investing.com | ||
| Mi | Arecor Therapeutics - Proposed Fundraising to raise up to £5.13 million | - | RNS | ||
| Mi | Arecor Therapeutics - Interim results for the six months to 30 June 2026 | - | RNS | ||
| 13.08. | Arecor veröffentlicht Studiendaten zu Insulinpräparat AT278 in Fachzeitschrift | 2 | Investing.com Deutsch | ||
| 13.08. | Arecor publishes AT278 study in peer-reviewed journal | 2 | Investing.com | ||
| 13.08. | Arecor Therapeutics - AT278 data published in peer-reviewed journal | - | RNS | ||
| 10.08. | Arecor Therapeutics - Holding(s) in Company | - | RNS | ||
| 28.05. | Arecor Therapeutics - Result of AGM | - | RNS | ||
| 21.05. | Arecor Therapeutics grants 455,000 stock options to executives | 1 | Investing.com | ||
| 21.05. | Arecor Therapeutics - Grant of options and PDMR dealing | - | RNS | ||
| 18.05. | Arecor Therapeutics - Upcoming conference attendance | - | RNS | ||
| 28.04. | Arecor Therapeutics - Posting of Annual Report and Notice of AGMm | - | RNS | ||
| 13.04. | Arecor Therapeutics swings to annual profit; hails insulin product | 4 | Alliance News |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 28,980 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,680 | -0,06 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 75,22 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 38,190 | -1,37 % | DAX-Gewinner im September: Die fünf Top-Aktien im DAX - Diese 5 Aktien ließen die Konkurrenz hinter sich | © Foto: Rafael Henrique - picture allianceDer September bringt Bewegung in den DAX. Auf 30-Tage-Sicht konnten vor allem Qiagen, MTU Aero Engines und die Commerzbank überzeugen. Ein Überblick über die... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,740 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 11,260 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized... ► Artikel lesen | |
| MBX BIOSCIENCES | 56,55 | 0,00 % | MBX Biosciences auf dem Stifel Cardiometabolic Forum: Pipeline setzt auf optimierte Dosierung | ||
| PRAXIS PRECISION MEDICINES | 287,06 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,070 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,810 | -0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| MODERNA | 168,82 | +0,40 % | Nur noch 4 Spritzen im Jahr?: Dieser Novo-Deal lässt eine kleine Pharma-Aktie um bis zu 161 % explodieren | © Foto: Steffen Trumpf - dpaNovo Nordisk sichert sich exklusiv eine Technologie, die Adipositas- und Diabetesmedikamente künftig deutlich seltener nötig machen könnte. Für Nanexa wird der Deal zum Börsenfeuerwerk... ► Artikel lesen | |
| PARABILIS MEDICINES | 30,440 | 0,00 % | Parabilis Medicines, Inc.: Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates | Advanced zolucatetide across multiple Wnt/ß-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,450 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 110,06 | -0,05 % | B.Riley reiterates Kymera Therapeutics stock rating on new trial data | ||
| RELAY THERAPEUTICS | 18,480 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates |
Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen |
ARECOR THERAPEUTICS PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,735 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARECOR THERAPEUTICS PLC finden Sie auf Wallstreet Online.